An observational study in Dermatophytosis, sponsored by Central Hospital, Nancy, France. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2025-12-09.
Sponsored by Central Hospital, Nancy, France · Observational
Superficial fungal infections (onychomycosis, dermatophytosis, tinea, etc.) caused by dermatophytes are common in the general population, affecting 20-25% worldwide (1, 2). In our practice, the most frequently observed clinical presentation is onychomycosis, with a prevalence ranging from 2% to 16.7% (3). However, diagnosing this fungal infection is challenging due to its lack of specificity and the long culture turnaround time (up to one month). A molecular approach could overcome these two limitations.
Currently, upon sample receipt, a direct mycological examination is performed alongside culture on specific media. If culture is positive, species or genus identification is carried out. Thus, the current reference method is a positive direct examination and/or a positive dermatophyte culture. Over the past four years (2020-2023), 49.85% of samples analyzed in our laboratory were positive (direct exam ± culture).
Several PCR kits are available for molecular detection of dermatophytes in skin and keratinous samples, and initial studies report promising performance: sensitivity ranging from 78.5% to 96.5% and specificity from 89.1% to 100%.
The study aims to determine the role of molecular diagnostics in these mycodermatological conditions and to compare the performance of two commercial kits.
Primary objective:
Determine the diagnostic performance of two molecular techniques for detecting dermatophytes.
The reference technique (gold standard) will be the presence of dermatophytes established by direct fungal examination. If the direct examination is negative, fungal culture will be performed for confirmation.
Secondary objectives:
Compare the diagnostic performance of the two molecular biology kits. Compare the average turnaround time for results.
39 studies on the registry are indexed under Tinea; 8 are open to participants now.
Browse Tinea studies →Central Hospital, Nancy, France is the lead sponsor of 798 studies on the registry; 186 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients consulting at CHRU Nancy for suspected dermatophyte infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
multiplex dermatophytes PCR
dermatophytes : yes / no and species involved
Time frame: 1 month
Ran from Dec 2024 to primary completion in Nov 2025, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →